Rising Pharma Recalls Duloxetine Due to N-nitroso-duloxetine Impurity: Commercial and Regulatory Impact
Rising Pharma Holding, Inc. initiated a Class II recall of 1,223 bottles of Duloxetine Delayed-Release Capsules, 30 mg, nationwide in the USA. This action, D-0277-2025, stems from CGMP deviations, specifically N-nitroso-duloxetine impurity exceeding interim limits. Procurement and regulatory teams must assess supplier quality controls and potential supply chain vulnerabilities for Duloxetine.
FDA Mandates Rising Pharma Duloxetine Recall Over N-nitroso Impurity
On March 5, 2025, Rising Pharma Holding, Inc., based in East Brunswick, NJ, initiated a Class II recall, identified as D-0277-2025, for 1,223 bottles of Duloxetine Delayed-Release Capsules, USP, 30 mg. This critical action, reported to the FDA on March 26, 2025, and classified on March 14, 2025, was necessitated by significant Current Good Manufacturing Practice (CGMP) deviations. Specifically, the affected product, from Lot #: DTB23111A with an expiration date of August 31, 2025, was found to contain N-nitroso-duloxetine impurity at levels exceeding the recommended interim limit. The product, distributed nationwide in the USA by Rising Health, LLC, Saddle Brook, NJ, 07663 (NDC 57237-018-99), represents a direct quality control failure. For procurement directors and regulatory affairs heads, this event underscores the persistent challenge of nitrosamine impurities within the pharmaceutical supply chain. The presence of N-nitroso-duloxetine above interim limits signals a fundamental breakdown in quality assurance processes at Rising Pharma. Companies sourcing active pharmaceutical ingredients (APIs) or finished drug products must immediately review their supplier qualification programs, particularly for generic manufacturers, to ensure robust impurity profiling and control strategies are in place. This recall necessitates a re-evaluation of risk assessments for all duloxetine-containing products in their portfolios.
Commercial Impact and Supply Chain Vulnerability for Duloxetine in the US Market
The recall of 1,223 bottles of Duloxetine Delayed-Release Capsules, USP, 30 mg, distributed nationwide across the USA, presents an immediate commercial challenge for Rising Pharma Holding, Inc. While the quantity may not represent a catastrophic market disruption for a widely prescribed generic antidepressant, it signals a critical quality lapse that can erode trust and impact future supply agreements. Each 1,000-count bottle (NDC 57237-018-99) targets institutional or high-volume dispensing, meaning the impact could be felt across various pharmacy chains and healthcare providers. For supply chain VPs and business development executives, this event highlights potential vulnerabilities in their Duloxetine supply. Although the recall is firm-initiated and classified as Class II (indicating potential for temporary or reversible adverse health consequences), the underlying CGMP deviations suggest systemic issues that could lead to further regulatory actions or future supply interruptions. Organizations reliant on Rising Pharma for Duloxetine must proactively assess their inventory levels, evaluate lead times for alternative suppliers, and initiate discussions with their legal and regulatory teams regarding contractual obligations and quality agreements. This incident serves as a clear directive to diversify sourcing strategies and ensure robust contingency plans are in place for essential generic medications.
Regulatory Scrutiny and Compliance Outlook for Rising Pharma Holding, Inc.
The Class II recall of Duloxetine Delayed-Release Capsules by Rising Pharma Holding, Inc. due to CGMP deviations and N-nitroso-duloxetine impurity places the company under heightened regulatory scrutiny from the FDA. While the recall was voluntarily initiated by the firm on March 5, 2025, the root cause—failure to adhere to Current Good Manufacturing Practices—is a serious concern that often precedes more stringent enforcement actions. Regulatory affairs heads must recognize that this incident will trigger increased oversight, potentially including facility inspections, data requests, and a requirement for comprehensive corrective and preventive actions (CAPA) plans. For business development executives considering partnerships or supply agreements with Rising Pharma, this event necessitates enhanced due diligence. The company's quality management systems, particularly those related to impurity control and nitrosamine risk assessment, will be under intense review. Future product approvals, manufacturing site transfers, or expansion into new markets could face delays or additional requirements until the FDA is satisfied with the remediation efforts. Companies must ensure that their supplier qualification processes include rigorous audits of CGMP compliance and a thorough understanding of a supplier's history with impurity-related recalls to mitigate their own regulatory and commercial risks.